MARKET COMPOSITE
TWST - Twist Bioscience Corp7:59:58 PM 3/28/2024
Price
$34.28
-0.20 (-0.58%)
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue71.5MM+7%
Gross Profit29MM-
Cost Of Revenue42.5MM+0%
Operating Income-47MM-6%
Operating Expenses75.9MM-
Net Income-43MM-7%
R&D23.1MM-3%
G&A52.8MM+11%
Amortization1.3MM-
Interest Expense0-100%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    SOUTH SAN FRANCISCO, Calif., March 28, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES).

    SOUTH SAN FRANCISCO, Calif., March 05, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products.

    SOUTH SAN FRANCISCO, Calif., February 22, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences:

    You can’t say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in. Of the top Cathie Wood stocks picked up in 2024, she’s bought $160 million worth of Tesla (NASDAQ:TSLA) for her Ark Invest family of funds even though the electric vehicle maker is down 22% this year. But you have to admire how Wood sticks to her guns. But Tesla isn’t the only big bet she’s making. In fact, the investing star is loading up on a numbe

    On February 8, 2024, Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), sold 4,110 shares of the company's stock, according to a recent SEC filing.

    SOUTH SAN FRANCISCO, Calif., February 07, 2024--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units ("RSUs") to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment i

    A week ago, Twist Bioscience Corporation ( NASDAQ:TWST ) came out with a strong set of first-quarter numbers that could...

    SOUTH SAN FRANCISCO, Calif. & SAN DIEGO, February 06, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

    SOUTH SAN FRANCISCO, Calif., February 06, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched the cfDNA Library Preparation Kit to enable liquid biopsy research.

    Twist Bioscience Corporation (NASDAQ:TWST) Q1 2024 Earnings Call Transcript February 2, 2024 Twist Bioscience Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to Twist Bioscience’s Fiscal 2024 First Quarter Financial Results Conference Call. At this time, all participants […]